Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 12/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12053889 | 0.94 | CNR1 (0.62) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4914356 | 0.94 | GABRA2 (0.60) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL2865960 | 0.93 | CNR1 (0.61) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4632916 | 0.91 | CNR1 (0.59) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL17163929 | 0.90 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL8016480 | 0.90 | CNR1 (0.58) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4184217 | 0.89 | CNR1 (0.53) | CNR1 | |
| SCHEMBL908827 | 0.89 | CNR2 (0.60) | CNR1CNR2 | |
| SCHEMBL8013842 | 0.89 | CNR1 (0.57) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4904008 | 0.88 | CNR1 (0.49) | CNR1CNR2GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632919-B1 | PYRAZOLE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2018-11-07 | — | — | EP | disclosed |
| CN-103459383-B | pyrazole compound | 财团法人国家卫生研究院 | 2016-06-22 | — | — | CN | disclosed |
| US-8962845-B2 | Pyrazole compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-02-24 | — | — | US | disclosed |
| US-8962845-B2 | Pyrazole compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-02-24 | — | — | US | disclosed |
| US-8962845-B2 | Pyrazole compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-02-24 | — | — | US | disclosed |
| CN-103459383-A | Pyrazole compound | NAT HEALTH RESEARCH INSTITUTES | 2013-12-18 | — | — | CN | disclosed |
| EP-2632919-A2 | PYRAZOLE COMPOUNDS | National Health Research Institutes (TW) | 2013-09-04 | — | — | EP | disclosed |
| US-20130085126-A1 | PYRAZOLE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-04-04 | — | — | US | disclosed |
| US-20130085126-A1 | PYRAZOLE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-04-04 | — | — | US | disclosed |
| WO-2013048989-A2 | PYRAZOLE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085126-A1 | PYRAZOLE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-04-04 | — | — | US | disclosed |
| WO-2009095752-A1 | FUSED PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
| EP-1928859-A1 | PYRAZOLE DERIVATES AS CANNABINOID RECEPTOR MODULATORS | Carex SA (FR) | 2008-06-11 | — | — | EP | disclosed |
| WO-2006133926-A1 | PYRAZOLE DERIVATES AS CANNABINOID RECEPTOR MODULATORS | CAREX SA (FR) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CNR1, CNR2, HCRTR2 | CNR1 1/4885CNR2 2/4885GABRA2 55/4885 |
| US-20130085126-A1 | PYRAZOLE COMPOUNDS | CYP3A43, CYP3A4, CYP3A7 | CNR1 353/4885CNR2 572/4885GABRA2 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.